Development of a rapid phenotypic test for HCV protease inhibitors with potential use in clinical decisions

Development of a rapid phenotypic test for HCV protease inhibitors with potential use in clinical decisions

Abstract Approximately 185 million people worldwide are chronically infected with hepatitis C virus (HCV). The first-wave of approved NS3 protease inhibitors (PIs) were Telaprevir and Boceprevir, which are currently discontinued. Simeprevir is a second-wave PI incorporated into the Brazilian hepatit...

Full description

Bibliographic Details
Main Authors: Luciana Santos Pessoa, Luãnna Liebscher Vidal, Emmerson C.B. da Costa, Celina Monteiro Abreu, Rodrigo Delvecchio da Cunha, Ana Luiza Chaves Valadão, André Felipe dos Santos, Amilcar Tanuri
Format: Article
Language:English
Published: Sociedade Brasileira de Genética
Series:Genetics and Molecular Biology
Subjects:
protease inhibitor
phenotypic test
hepatitis C virus
HCV NS3 protease
resistance mutation
Online Access:http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1415-47572016000300358&lng=en&tlng=en

Internet

http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1415-47572016000300358&lng=en&tlng=en

Similar Items